Search

Your search keyword '"Loghavi, Sanam"' showing total 1,284 results

Search Constraints

Start Over You searched for: Author "Loghavi, Sanam" Remove constraint Author: "Loghavi, Sanam"
1,284 results on '"Loghavi, Sanam"'

Search Results

1. Virtual Pathology Elective, Real Education: The PathElective.com Experience as a Model for Novel Pathology Pedagogy and a Primer for Curricular Evolution

2. Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia

3. Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes

5. Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia

6. Characteristics and outcomes of children, adolescent, and young adult patients with myelodysplastic neoplasms: A single-center retrospective analysis

7. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

8. Plasmablastic Lymphoma

13. Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia

15. BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor

17. Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents

18. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis

22. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy

24. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax

27. Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes—Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes

29. Immune evasion phenotype is common in Richter transformation diffuse large B-cell lymphoma variant

30. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia

31. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)

33. Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes

34. Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms

37. Including International Medical Graduates in Diversity, Equity, and Inclusion Conversations Among Pathology Training Programs

38. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)

39. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome

40. Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma

41. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

42. Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes

43. Undetectable Measurable Residual Disease is Associated with Improved Outcomes in AML Irrespective of Treatment Intensity

44. TP53 Y220C mutations in patients with myeloid malignancies

45. Detection of PNH clones can aid in the distinction of aplastic anemia vs inherited BM failure syndromes: a single center experience and review of the literature.

46. FLAG-IDA + venetoclax in newly diagnosed (ND) or relapsed/refractory (RR) AML.

47. Outcomes of patients with bone marrow fibrosis in de novo and secondary acute myeloid leukemia.

Catalog

Books, media, physical & digital resources